Structural elucidation of impurities in 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichlorophenyl)-3H-1,2,4-triazol-3-one (Ib), a novel nonpeptide angiotensin AT1 receptor antagonist

Journal of Pharmaceutical and Biomedical Analysis

Volumn 66, Issue , 2012, Pages 381-386

  Gao, Ting ^a,b   Liu, Yaxuan ^a,b   Ji, Yibing ^a,b   Wu, Xiaoming ^b   Xu, Jinyi ^b  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Ib; Impurity; Mass spectrometry; NMR; Structural elucidation

Indexed keywords

5 N BUTYL 4 [ 4 [2 (1H TETRAZOLE 5 YL) 1H PYRROL 1 YL]PHENYLMETHYL] 2,4 DIHYDRO 2 (2,6 DICHLOROPHENYL) 3H 1,2,4 TRIAZOL 3 ONE; 5 N BUTYL 4 [4 [2 BROMO 5 (1H TETRAZOLE 5 YL) 1H PYRROL 1 YL]PHENYLMETHYL] 2,4 DIHYDRO 2 (2,6 DICHLOROPHENYL) 3H 1,2,4 TRIAZOL 3 ONE; 5 N BUTYL 4 [4 [2 CHLORO 5 (1H TETRAZOLE 5 YL) 1H PYRROL 1 YL]PHENYLMETHYL] 2,4 DIHYDRO 2 (2,6 DICHLOROPHENYL) 3H 1,2,4 TRIAZOL 3 ONE; 5 N BUTYL 4 [4 [4 BROMO 2 (1H TETRAZOLE 5 YL) 1H PYRROL 1 YL]PHENYLMETHYL] 2,4 DIHYDRO 2 (2,6 DICHLOROPHENYL) 3H 1,2,4 TRIAZOL 3 ONE; 5 N BUTYL 4 [4 [4 CHLORO 2 (1H TETRAZOLE 5 YL) 1H PYRROL 1 YL]PHENYLMETHYL] 2,4 DIHYDRO 2 (2,6 DICHLOROPHENYL) 3H 1,2,4 TRIAZOL 3 ONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; N BROMOSUCCINIMIDE; UNCLASSIFIED DRUG;

ARTICLE; BROMINATION; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG IMPURITY; DRUG ISOLATION; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; HETERONUCLEAR MULTIPLE BOND CORRELATION; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; INFRARED SPECTROMETRY; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TANDEM MASS SPECTROMETRY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DRUG CONTAMINATION; HALOGENATION; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TETRAZOLES; TRIAZOLES;

EID: 84861221117     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.03.031     Document Type: Article

References (6)

1. Xu J.Y., Zhou Y.X., Wu X.M., Tang K., Wang Q.J. Synthesis and bioactivity of 1-aryl-3-alkyl-1,4-dihydro-4-substitued-5H-1,2,4,-triazolinones-5. J. China Pharm. Univ. 1999, 30:323-327.
2. Wang Y., Wang W., Wang Q.J., Wu J.H., Xu J.Y., Wu X.M. [Ca2+]i and PKC-α are involved in the inhibitory effects of Ib, a novel nonpeptide angiotensin II subtype AT1 receptor antagonist, on angiotensin II-induced vascular contraction in vitro. Biochem. Biophys. Res. Commun. 2007, 364:118-123.
3. Wu J.H., Wang Q.J., Guo J.Y., Hu Z.Y., Yin Z.Y., Xu J.Y., Wu X.M. Characterization of angiotensin II antagonism displayed by Ib, a novel nonpeptide angiotensin AT1 receptor antagonist. Eur. J. Pharmacol. 2008, 589:220-224.
4. Wu J.H., Wang Q.J., Hu S., Xu J.Y., Wu X.M. Antihypertensive effects of a new angiotensin type 1 receptor antagonist 1b on rats. J. China Pharm. Univ. 2005, 36:563-566.
5. Zhang J., Wang Q.J., Xu J.Y., Wu X.M. Effects of a new angiotensin type 1 receptor antagonist 1b on the cardiac hypertrophy induced by l-thyroxin in rat. J. China Pharm. Univ. 2006, 37:157-160.
6. International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, ICH Q3A(R). Impurities in New Drug Substances 2003, pp. 1-13.